§ GLP-1 & Weight Loss
Tirzepatide
A dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound) with the largest randomized weight-loss results to date.
Fact-checked 12 May 2026Plain-English Reference
Tirzepatide activates both the GIP and GLP-1 receptors, producing a more pronounced effect on appetite and energy intake than single-agonist GLP-1s. SURMOUNT-1 reported a 20.9% mean weight loss at 72 weeks on the 15 mg dose. Tirzepatide is sold as Mounjaro (T2D) and Zepbound (chronic weight management).
§ Where Tirzepatide Comes Up